-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
-
Summary
-
Sunshine Biopharma Inc. annual/quarterly Amortization of Intangible Assets history and growth rate from Q1 2021 to Q4 2023.
- Sunshine Biopharma Inc. Amortization of Intangible Assets for the quarter ending December 31, 2023 was $11.7K.
- Sunshine Biopharma Inc. Amortization of Intangible Assets for the twelve months ending December 31, 2023 was $38.4K.
- Sunshine Biopharma Inc. annual Amortization of Intangible Assets for 2024 was $77K, a 100% increase from 2023.
- Sunshine Biopharma Inc. annual Amortization of Intangible Assets for 2023 was $38.4K.
- Sunshine Biopharma Inc. annual Amortization of Intangible Assets for 2021 was $58.9K, unchanged from 2020.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)